CHRS EBITDA Growth
Coherus Oncology Inc · EBITDA Growth
CHRS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-10.85%period ending
CHRS TTM EBITDA YoY % (-60.53% → -10.85%)
Year-over-year change
High-resolution chart · PNG
CHRS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| -10.8491% | |
| -61.8739% | |
| -44.2756% | |
| -20.9657% | |
| 19.6284% | |
| 48.6385% | |
| 39.1726% | |
| 18.7961% | |
| 25.4972% | |
| 17.9338% | |
| 24.1184% | |
| 29.0043% | |
| -12.1668% | |
| -30.1701% | |
| 1.7367% | |
| -20.2295% | |
| -44.5054% | |
| -273.1802% | |
| -262.8055% | |
| -207.9356% | |
| -166.3315% | |
| -128.4197% | |
| 41.2843% | |
| 2,717.3538% | |
| 303.7921% | |
| 199.4748% | |
| 157.5491% | |
| 103.678% | |
| 44.196% | |
| 12.3893% | |
| 12.8072% | |
| 27.6174% | |
| -67.0222% | |
| -62.1779% | |
| -100.9676% | |
| -178.6372% | |
| 55.911% | |
| 50.8499% | |
| 49.326% | |
| 53.5612% | |
| -88.2572% | |
| -151.6056% | |
| -180.7921% | |
| -200.0877% | |
| -72.1366% | |
| -56.4615% | |
| -60.5337% |